Non-cytotoxic protein conjugates
AssigneesAllergan, Inc., Syntaxin Limited
InventorsKeith FOSTER, John CHADDOCK, Charles PENN, Kei Roger AOKI, Joseph FRANCIS, Lance STEWARD
Life of this patent
Estimating the term…
Loading patent…
AssigneesAllergan, Inc., Syntaxin Limited
InventorsKeith FOSTER, John CHADDOCK, Charles PENN, Kei Roger AOKI, Joseph FRANCIS, Lance STEWARD
Estimating the term…
The present invention is directed to non-cytotoxic protein conjugates for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell. The protein conjugates comprise: (i) a dynorphin Targeting Moiety (TM), wherein the TM is an agonist of a receptor present on a nociceptive sensory afferent cell, and wherein the receptor undergoes endocytosis to be incorporated into an endosome within the nociceptive sensory afferent cell; (ii) a non-cytotoxic protease or a fragment thereof, wherein the protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of the nociceptive sensory afferent cell; and (iii) a Translocation Domain, wherein the Translocation Domain translocates the protease or protease fragment from within the endosome, across the endosomal membrane, and into the cytosol of the nociceptive sensory afferent cell. Nucleic acid sequences encoding the protein conjugates, methods of preparing same and uses thereof are also described.
An isolated polynucleotide molecule comprising a polynucleotide encoding a non-cytotoxic protein conjugate for inhibition or reduction of exocytic fusion in a nociceptive sensory afferent cell, comprising:
An isolated polynucleotide molecule comprising a polynucleotide encoding the amino acid sequence of any one of SEQ ID NOs:103, 104, 105, 106, 107, 108, and 109.
An isolated polynucleotide molecule comprising the nucleic acid sequence set forth in SEQ ID NO:102.
Dependencies are inferred from the claim text.